Clinical trial
Reduced-Dose Thrombolysis in Intermediate-High Risk Pulmonary Embolism, a Multicenter, Randomized Controlled Trial
NCT07917078 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Reduced-Dose Thrombolysis in Intermediate-High Risk Pulmonary Embolism, a Multicenter, Randomized Controlled Trial
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- November 1, 2026
- Completion date
- December 31, 2029
- Enrollment
- 270 (estimated)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 2 arms.
-
Reduced-Dose Alteplase and Standard Anticoagulation
Low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) and reduced-dose alteplase \[25 mg continuous intravenous infusion for 2 hours\]
-
Standard Anticoagulation
Low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH)
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change in the ratio of right ventricular end-diastolic diameter to left ventricular end-diastolic diameter (RVED/LVED) as measured by echocardiography
Lead sponsor's other trials
China National Center for Cardiovascular Diseases, most recent start first.
+264 more trials See the organization page
Similar trials
Same condition (Pulmonary Embolism) and phase, most recent start first.
+67 more trials See the condition page